Department of Clinical Genetics, Odense University Hospital, Sdr, Boulevard 29, Odense 5000, Denmark.
BMC Med Genomics. 2014 Jan 31;7:9. doi: 10.1186/1755-8794-7-9.
In more than 70% of families with a strong history of breast and ovarian cancers, pathogenic mutation in BRCA1 or BRCA2 cannot be identified, even though hereditary factors are expected to be involved. It has been proposed that tumors with similar molecular phenotypes also share similar underlying pathophysiological mechanisms. In the current study, the aim was to investigate if global RNA profiling can be used to identify functional subgroups within breast tumors from families tested negative for BRCA1/2 germline mutations and how these subgroupings relate to different breast cancer patients within the same family.
In the current study we analyzed a collection of 70 frozen breast tumor biopsies from a total of 58 families by global RNA profiling and promoter methylation analysis.
We show that distinct functional subgroupings, similar to the intrinsic molecular breast cancer subtypes, exist among non-BRCA1/2 breast cancers. The distribution of subtypes was markedly different from the distribution found among BRCA1/2 mutation carriers. From 11 breast cancer families, breast tumor biopsies from more than one affected family member were included in the study. Notably, in 8 of these families we found that patients from the same family shared the same tumor subtype, showing a tendency of familial aggregation of tumor subtypes (p-value = 1.7e-3). Using our previously developed BRCA1/2-signatures, we identified 7 non-BRCA1/2 tumors with a BRCA1-like molecular phenotype and provide evidence for epigenetic inactivation of BRCA1 in three of the tumors. In addition, 7 BRCA2-like tumors were found.
Our finding indicates involvement of hereditary factors in non-BRCA1/2 breast cancer families in which family members may carry genetic susceptibility not just to breast cancer but to a particular subtype of breast cancer. This is the first study to provide a biological link between breast cancers from family members of high-risk non-BRCA1/2 families in a systematic manner, suggesting that future genetic analysis may benefit from subgrouping families into molecularly homogeneous subtypes in order to search for new high penetrance susceptibility genes.
在超过 70%具有强烈乳腺癌和卵巢癌家族史的家庭中,即使存在遗传因素,也无法确定 BRCA1 或 BRCA2 中的致病性突变。有人提出,具有相似分子表型的肿瘤也具有相似的潜在病理生理机制。在本研究中,我们旨在研究是否可以使用全局 RNA 分析来鉴定经 BRCA1/2 种系突变检测为阴性的家族中的乳腺癌肿瘤中的功能亚群,以及这些亚群如何与同一家庭中的不同乳腺癌患者相关。
在本研究中,我们通过全局 RNA 分析和启动子甲基化分析,分析了来自 58 个家族的总共 70 个冷冻乳腺癌活检样本。
我们表明,在非 BRCA1/2 乳腺癌中存在与固有分子乳腺癌亚型相似的独特功能亚群。亚型的分布与 BRCA1/2 突变携带者中的分布明显不同。从 11 个乳腺癌家族中,该研究纳入了来自多个受影响家族成员的乳腺癌活检样本。值得注意的是,在其中 8 个家族中,我们发现来自同一家庭的患者具有相同的肿瘤亚型,表明肿瘤亚型具有家族聚集的趋势(p 值=1.7e-3)。使用我们先前开发的 BRCA1/2 特征,我们鉴定了 7 个具有 BRCA1 样分子表型的非 BRCA1/2 肿瘤,并为其中 3 个肿瘤中 BRCA1 的表观遗传失活提供了证据。此外,还发现了 7 个 BRCA2 样肿瘤。
我们的发现表明,遗传因素参与了非 BRCA1/2 乳腺癌家族,这些家族成员可能不仅易患乳腺癌,而且易患特定类型的乳腺癌。这是第一项系统地提供高风险非 BRCA1/2 家族成员乳腺癌之间生物学联系的研究,表明未来的遗传分析可能受益于将家族按分子同质性亚组分组,以寻找新的高外显率易感基因。